Revenue
2022
2023
2024
2025
Artelo Biosciences, Inc. (ARTL)
Price$6.04Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2021
2022
2023
2024
2025
Free cash flow
2018
2019
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 · Dec 31 | 2021 · Aug 31 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Research & development | $5.4M | $6.0M | $5.7M | $4.3M | $3.8M | $2.8M | $1.9M | $1.1M | $1.2M | — | — | — | — |
| Operating expenses | $11.4M | $10.1M | $9.9M | $10.3M | $9.4M | $7.4M | $4.7M | $3.2M | $2.3M | $232,789 | $29,690 | $15,241 | $15,269 |
| Operating income | −$11.4M | −$10.1M | −$9.9M | −$10.3M | −$9.4M | −$7.4M | −$4.7M | −$3.2M | −$2.3M | −$232,789 | −$29,690 | −$15,241 | −$15,269 |
| EBITDA | −$12.6M | −$9.8M | −$9.9M | −$10.1M | — | — | −$4.7M | −$3.2M | −$2.3M | — | — | — | — |
| Net income | −$12.9M | −$9.8M | −$9.3M | −$10.1M | −$9.4M | −$7.4M | −$4.7M | −$2.2M | −$2.3M | −$234,889 | −$29,690 | −$15,241 | −$15,269 |
| Basic EPSper basic share | -$37.56 | -$54.90 | -$56.52 | -$64.08 | — | -$0.02 | -$56.70 | -$45.00 | -$82.80 | -$10.80 | $0.00 | $0.00 | $0.00 |
| Diluted EPSper diluted share | -$37.56 | -$54.90 | -$9.42 | -$64.08 | — | -$0.02 | -$56.70 | -$65.70 | -$82.80 | -$10.80 | $0.00 | $0.00 | $0.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
JANE STREET GROUP, LLC | 66.34K |
GEODE CAPITAL MANAGEMENT, LLC | 13.86K |
StoneX Group Inc. | 12.4K |
VANGUARD CAPITAL MANAGEMENT LLC | 10.13K |
Tower Research Capital LLC (TRC) | 8.44K |
VANGUARD FIDUCIARY TRUST CO | 3.14K |
UBS Group AG | 2.8K |
ROTHSCHILD INVESTMENT LLC | 2 |
TD Waterhouse Canada Inc. | 2 |
DANSKE BANK A/S | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2025Form 4 | FAVORITO TAMARA ADirector | BuyConvertible Promissory Note · derivative · indirect | — | $25.0K | $25.0K | — |
| May 1, 2025Form 4 | MATSUI CONNIEDirector | BuyConvertible Promissory Note · derivative | — | $140.0K | $140.0K | — |
| May 1, 2025Form 4 | Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr | BuyConvertible Promissory Note · derivative | — | $35.0K | $35.0K | — |